AIM ImmunoTech
7 hedge funds and large institutions have $362K invested in AIM ImmunoTech in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 8 closing their positions.
89% more capital invested
Capital invested by funds: $192K → $362K (+$170K)
42% less funds holding
Funds holding: 12 → 7 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$368K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$60.5K |
| 3 |
APA
American Portfolios Advisors
Holbrook,
New York
|
+$1.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$58K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$16.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$11K |
| 4 |
VF
Virtu Financial
New York
|
-$11K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $267K | +$368K | +609 | New |
|
2
BlackRock
New York
| $46K | – | – | – |
|
|
ARTA
3
A.R.T. Advisors
New York
| $44K | +$60.5K | +100 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $4K | -$16.9K | -28 | -76% |
|
|
APA
5
American Portfolios Advisors
Holbrook,
New York
| $1K | +$1.21K | +2 | New |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| – | -$58K | -82 | Closed |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| – | -$11K | -17 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$11K | -15 | Closed |
|
|
9
Northern Trust
Chicago,
Illinois
| – | -$5K | -7 | Closed |
|
|
OAM
10
Occidental Asset Management
Burlingame,
California
| – | -$3K | -4 | Closed |
|
|
WPW
11
Waldron Private Wealth
Bridgeville,
Pennsylvania
| – | -$1K | -3 | Closed |
|
|
TSS
12
Two Sigma Securities
New York
| – | -$2K | -2 | Closed |
|
|
AG
13
Advisor Group
Phoenix,
Arizona
| – | -$605 | -1 | Closed |
|
AIM Hedge Fund Activity: Q2 2019 in Review
7 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2019, worth a combined $362K — up 89% from $192K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of AIM and 3 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $368K. The largest seller was Vanguard Group, exiting entirely with an estimated $58K sold.
- 7 institutional investors held AIM ImmunoTech (AIM) as of Q2 2019, down from 12 in Q1 2019.
- Funds reported $362K of AIM ImmunoTech stock for Q2 2019, up 89% quarter-over-quarter.
- 3 funds opened new AIM ImmunoTech positions in Q2 2019 and 8 closed out, a net change of -5 holders.
- The largest AIM ImmunoTech buyer in Q2 2019 was Sabby Management, an estimated $368K added.
- The largest AIM ImmunoTech seller in Q2 2019 was Vanguard Group, an estimated $58K sold.
Based on aggregated 13F filings for Q2 2019.